Ozempic cuts risk of death from kidney disease, major study finds
Novo Nordisk, the maker of Ozempic will seek FDA approval to dramatically expand the number of patients eligible for the shots.
Source: pressherald.com
Stay updated with breaking news from Peter Verdult. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Novo Nordisk, the maker of Ozempic will seek FDA approval to dramatically expand the number of patients eligible for the shots.
Operator: Ladies and gentlemen, welcome to the Evotec SE Quarterly Statement Q1 2024 Conference Call. I am Sandra, the chorus call operator.
Daniel Segarra: Hello, everyone, and welcome to Grifols' Conference Call. Today, we will be sharing a business update on our first quarter financial results.
NVO earnings call for the period ending March 31, 2024.
Evotec SE misses on earnings expectations. Reported EPS is $-0.05 EPS, expectations were $-0.03333.